Diagnosis & Disease Information

SN-MMR was strongly associated with OS, melanoma-specific survival, and DFS among patients with a po

ASCO 2020 Lung Cancer In-Depth

KEYNOTE-604: Pembrolizumab Missed OS Endpoint in First-Line SCLC, but Appeared to Prolong Survival in Some Patients

Leah Lawrence

June 15, 2020

The drug did, however, significantly improve progression-free survival.

Targeted and immunotherapies appear to be opening a new frontier in the management of elderly patien

ASCO 2020 Lung Cancer In-Depth

Researchers Present Evidence in Support of Broad Next-Generation Sequencing in Advanced Nonsquamous NSCLC

Randi Hernandez

June 12, 2020

Though they are costly, broad genetic assays that look for many gene mutations at once may confer more value overall than a one-off testing approach for patients with nsNSCLC.

MRI scan of the abdomen highlighting small cell lung cancer (SCLC).

ASCO 2020 Lung Cancer In-Depth

Nivolumab Plus Ipilimumab Yields Long-Term Responses in Advanced NSCLC

Jonathan Goodman, MPhil

June 11, 2020

Overall, grade 3 to 4 AEs were noted in 33% of patients receiving the immunotherapy combination vs 36% of patients receiving chemotherapy.

ASCO 2020 Lung Cancer In-Depth

Bintrafusp Alfa: Durable Responses Noted in NSCLC

Jonathan Goodman, MPhil

June 11, 2020

In the 3 ongoing responses, all had PD-L1–positive disease.

KRAS encodes an enzyme that is involved in cell signal transduction, and is related to cell growth, proliferation, and differentiation. A single nucleotide mutation on KRAS results in an oncogenic protein that is implicated in lung and other cancers; KRAS mutations are more common among patients with a history of smoking. While identifying a KRAS mutation is useful in predicting how well patients will respond to EGFR TKI therapy, there are as yet no therapies that are specifically tailored to attack KRAS.15

ASCO 2020 Lung Cancer In-Depth

Pralsetinib Appears Promising in RET Fusion-Positive NSCLC

Jonathan Goodman, MPhil

June 11, 2020

Three of 9 patients with measurable central nervous system metastases had an intracranial complete response, with a 56% overall response rate in this subgroup.

ASCO 2020 Lung Cancer In-Depth

HER2-Positive NSCLC: Trastuzumab Deruxtecan Shows Promising Activity

Jonathan Goodman, MPhil

June 11, 2020

Twenty-six (61.9%) patients had an ORR as confirmed by independent central review.

Next post in ASCO 2020 Lung Cancer In-Depth